Daewoong Pharmaceutical's Envlo Wins Marketing Approval in Mexico, Now Authorized in Seven Latin American Countries
Sequential Launch Planned in Local Markets
Daewoong Pharmaceutical announced on May 27 that it has obtained marketing approval in Mexico for Envlo (ingredient name: inavogliflozin), its type 2 diabetes treatment. With this, the company has expanded its presence in Latin America to a total of seven countries, accelerating its global expansion strategy.
Product image of Enblo, a type 2 diabetes treatment in the SGLT-2 inhibitor class developed by Daewoong Pharmaceutical. Daewoong Pharmaceutical
View original imageThis approval is part of Daewoong Pharmaceutical’s strategy to secure regulatory approvals for Envlo in 12 Latin American countries. The company has already signed supply agreements with its local partner Arcera (formerly Moksha8) for key markets, including Brazil and Mexico.
Daewoong Pharmaceutical explained that, since the majority of Latin America's total economic output is concentrated in these 12 countries, it expects a significant first-mover advantage in the region’s major markets. Starting this year, the company plans to sequentially launch its product throughout Latin America, leveraging local distribution networks.
Envlo is a domestically developed new drug in the SGLT-2 inhibitor class, created by Daewoong Pharmaceutical. Its mechanism involves lowering blood sugar by inhibiting the reabsorption of glucose in the kidneys. The company noted that Envlo demonstrated a similar glucose-lowering effect at a low dose of 0.3 mg, compared to existing SGLT-2 inhibitors.
Daewoong Pharmaceutical also reported that Envlo showed the potential to improve several indicators in patients with diabetes and impaired renal function, including the urinary glucose-to-creatinine ratio (UGCR), insulin resistance index (HOMA-IR), albuminuria, and NT-proBNP.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Sungsoo Park, CEO of Daewoong Pharmaceutical, stated, "This approval in Mexico is the first result of our strategy to expand into the Latin American market. We plan to accelerate local commercialization and broaden supply across the entire region."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.